Gene & Cell Therapy Development.
Rational Design and Efficient Process Controls.
Cell therapies such as CAR-T and CAR-NK become more efficacious and cost effective through (1) automation and improvements in process control and (2) improved CAR design. Next generation protein sequencing (NGPS) allows discovery of (or understanding and engineering of) scFv and hinge regions from IgG for modulation of binding affinity, epitopic activity and FcγR activity – key insights for rational design. NGPS also allows for rapid assay development by finding and engineering good binders, identification of PTMs, development of enrichment tools for manufacturing/production, as well as development of validation tools for in vivo assessments.
Gene therapies require study by NGPS in order to identify PTMs associated with viral vectors (e.g. AAV) and to sequence, study, and engineer the viral capsid protein.
Services for Cell and Gene Therapy Design.
We support cell and gene therapy design and manufacturing processes. Contact us to discover how we can help with your CAR-T cell, or gene therapy application.
Antibody Sequencing & Discovery Services.
De Novo mAb Sequencing
Sequence antibodies known to bind to your target, in order to engineer new cell receptors. Easily develop enrichment, detection, and validation tools, as well as assays for manufacturing QC by sequencing mAbs.
Explore Antibody Sequencing Service
Novel scFv Discovery
Discover new antigen binding regions by examining the functional native immune response and sequencing patient antibodies.
Explore Antibody Discovery Services
Protein Engineering and Expression
Species switching. Fc silencing. Start by sequencing what works, then engineer, express and confirm your sequence before proceeding.
Explore Peptide Mapping Services
Capsid Protein Sequencing
Sequencing of mAbs, scFvs, and Fabs for the rational design of capsid proteins for improved transduction and immunogenicity.
Explore Protein Sequencing Services
Capsid Antigenic HDX-MS Epitope Mapping
Understand how antibodies interact with the AAV capsid by characterizing capsid antigenic epitopes, for rational engineering of AAVs.
Explore Epitope Mapping Services
SPR Binding Kinetics
Obtain binding kinetic information on neutralizing antibodies (NAbs) to characterize the mechanisms behind AAV neutralization and immunity.
Explore SPR Service
Application Publications.
Generation and Optimization of Off-The-Shelf Immunotherapeutics Targeting TCR-Vβ2+ T Cell Malignancy
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
CAR-iNKT Cells Targeting Clonal TCRVβ Chains as a Precise Strategy to Treat T Cell Lymphoma
With 22 functional T cell receptor (TCR)Vβ subunit families making up the normal T cell repertoire, signals from these cell surface receptors often determine the fate of normal cells. However, mutations in TCR signaling proteins are frequently associated with peripheral T cell lymphomas (TCLs), including adult T cell leukemia/lymphoma (ATL), which indicates a driving role for TCRs in TCL oncogenesis. As TCL and ATL are clonal in nature, tumour cells typically express a single TCRVβ subunit with no bias in the usage of TCRVβ subunit families. Consequently, targeting the specific TCRVβ subunit presents a promising therapeutic approach that is highly selective and tumour-specific.
Towards Antigen-Specific Tregs for Type 1 Diabetes: Construction and Functional Assessment of Pancreatic Endocrine Marker, HPi2-Based Chimeric Antigen Receptor
Antibodies with established, specific targets can be sequenced and utilized to engineer the hinge region and antigen-binding domains with antibody fragments and derivatives. With the sequence information in hand, further steps to optimizing a viable therapeutic approach can be more accessible.
Chimeric Antigen Receptors and T cells – CAR-T
Written by: Vanessa Yoon Calvelo, PhD Published: June 13, 2022 Contents What is CAR-T Cell Therapy? [...]
“We’re focused on coupling cytokines with a highly engineered VHVL of an antibody. So by sequencing the antibodies with Rapid Novor we are able to pull out the CDR to graft them into our platform and test in vitro and in vivo.”
Pavel Khrimian – Co-founder and CBO, Deka Biosciences
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics